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Abstract
We describe three statistical results that we have found to be useful in case-control genetic association testing. All three
involve combining the discovery of novel genetic variants, usually by sequencing, with genotyping methods that recognize
previously discovered variants. We first consider expanding the list of known variants by concentrating variant-discovery in
cases. Although the naive inclusion of cases-only sequencing data would create a bias, we show that some sequencing data
may be retained, even if controls are not sequenced. Furthermore, for alleles of intermediate frequency, cases-only
sequencing with bias-correction entails little if any loss of power, compared to dividing the same sequencing effort among
cases and controls. Secondly, we investigate more strongly focused variant discovery to obtain a greater enrichment for
disease-related variants. We show how case status, family history, and marker sharing enrich the discovery set by increments
that are multiplicative with penetrance, enabling the preferential discovery of high-penetrance variants. A third result
applies when sequencing is the primary means of counting alleles in both cases and controls, but a supplementary pooled
genotyping sample is used to identify the variants that are very rare. We show that this raises no validity issues, and we
evaluate a less expensive and more adaptive approach to judging rarity, based on group-specific variants. We demonstrate
the important and unusual caveat that this method requires equal sample sizes for validity. These three results can be used
to more efficiently detect the association of rare genetic variants with disease.
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Introduction
We address some statistical issues raised by the discovery of new
genetic variants in the context of case-control association studies.
We focus our attention on individual genes, partly for simplicity,
and partly because the selection of cases for sequencing can be
taken somewhat further in the candidate gene setting. Genome-
wide association (GWA) studies are generally based on established
sets of single-nucleotide polymorphisms (SNPs). Because the
coverage of rare alleles by combinations of known SNPs is limited
[1], an investigator may wish to identify potentially causal
mutations near a GWA hit, or take a closer look at a candiate
gene. There are cost-limitations on how much of the genome can
be covered [2]. Even with genome-wide resequencing of expressed
genes, an investigator may need a locus-focused effort to discover
variation in regulatory regions, or there may me a need to probe
for the newly-discovered variants in a larger set of individuals. Any
of these situations is likely to raise the issues we addess.
Another general development motivating this work is the
increasing interest in rare variants [3]. Pritchard [4] for example,
argues that much of the genetic variance underlying disease may
be due to high mutation rates into the high-risk class. While the
total frequency of susceptibility mutations may be high in this
situation, there will be extensive allelic heterogenity. It is also
reasonable to expect that high penetrance alleles will be
individually rare due to selection pressure. Dickson et al. [5] note
that rare variants can create synthetic associations that may
account for GWA results. It is an even greater problem when
synthetic association is not present. High-penetrance rare alleles
may be invisible to GWA studies if they are spread too evenly
across SNP-tagged haplotypes. In such cases, sequencing, or an
equivalent variant-discovery method, may be the only way to
identify a disease association.
Throughout the paper, we consider rare alleles collectively. This
is partly because their numbers may not otherwise accumulate
enough to be distinguished from random events, but also because
such testing associates the gene with the phenotype. The disease
association of a specific SNP haplotype at a locus, presumably due
to its linkage disequilbrium with undetected genetic lesions, is not
necessarily more informative than the disease association of a set of
rare sequences, and the former situation may resemble the latter
upon sequencing of the haplotype. Collective testing permits alleles
to be grouped according to an hypothesis, rather than by the
accidents of linkage disequilibrium. The hypothesis might involve
additional information, such as change to the protein sequence,
evolutionary conservation, or initial detection in selected cases.
Even when alleles of moderate frequency are involved,
collective testing has a power advantage. Slager et al. [6] note
that allelic heterogeneity reduces the power of association tests.
Longmate [7] notes that tests with multiple degrees of freedom are
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priori collection can be still more powerful, while retaining
substantial robustness to misclassification. Li and Leal [8] make
similar points, but add a method for combining a test of rare
variants as a collective with an omnidirectional test of more
common alleles. The advantage of such a combined test seems to
apply when it is the common alleles, rather than the rare, that are
most strongly associated with disease. Our interest being primarily
in the reverse situation, we focus here on the collective testing of
rare variants, deliberately excluding common alleles.
Our results address three questions. First, we consider
expanding the catalogue of known sequence variation prior to
genotyping a much larger number of cases and controls. This
assumes that the genotyping will probe for all of the discovered
variants, and not just a standard collection of SNPs. We show that
sequencing can focus initially on cases, to obtain a sample of the
allelic heterogeneity associated with disease, and that sequencing
of controls is not always necessary.
Second, we ask to what extent can we enhance our discovery of
trait-related variants by focusing resequencing efforts more
strongly within cases. Even low-resolution genotyping can guide
sequencing for this purpose by identifying a subset of cases who
share markers with an affected relative. A general pattern we find
is that the enrichment due to selection increases multiplicatively
with increasing penetrance.
Our third question arises when sequencing is used to both
discover and count variants in cases and controls, and we wish to
focus our comparison on rare alleles. We show that genotyping in
supplementary pooled samples, to establish rarity, raises no
validity issues, and that the use of group-specific variant detection,
which avoids the need for additional genotyping, requires equal
sample sizes for validity.
Results
Following Altshuler et al. [9], we distinguish three classes of allele
frequencies. Common alleles, with frequencies above 5 percent,
are well covered by the current HapMap. We will refer to variants
with frequencies between 0.5% and 5% as uncommon. These are
common enough to catalogue, but are not well covered at present.
Rare mutations will be difficult to catalogue comprehensively [10].
Sequencing cases for variant discovery
Resequencing a subset of individuals can be used to expand the
catalogue of variants that less expensive genotyping methods will
recognize in the remaining individuals. The use of diseased as
opposed to neutral discovery panels can enrich the catalogue for
disease-associated variants in the population being investigated
[10,11].
When the detection of variants is concentrated among cases, it is
not valid to compare the resulting counts to those obtained by
probing only for those same alleles among controls. As an extreme
example, imagine a locus prone to mutation, with many unique
variants. Sequencing cases would find many variants not found in
controls, but sequencing controls would likely find as many
variants not found in cases, and neither disparity would have
anything to do with the disease.
An allele that is uncommon but not rare might be encountered
several times among the sequenced cases, particularly if the cases
chosen for sequencing are heavily selected. One would not want to
simply discard all sequenced cases when counting alleles for an
association test. Li and Leal [10] address the size of the bias
introduced when variant discovery is limited to cases. Here we use
a standard result in size-biased sampling to show that an unbiased
test may be obtained by discarding only the first example of each
allele encountered during allele discovery. Subsequent encounters
may be retained.
Consider a test in which individuals are simply scored as to
whether or not they exhibit a specific variant, and that the variant
came to our attention through sequencing of cases, but not
controls. Let p be the probability that a sampled individual
possesses the variant. Let X be the (possibly unobserved) number
of individuals possessing the variant among the n cases in the
sample, and denote the binomial distribution of X as B(n,p).W e
draw a sub-sample of m cases to be screened for allelic variants,
and let Y be the number of individuals with the variant in this sub-
sample. If Y~0, the allele is not detected, and we will not observe
X.I fYw0, the allele will be detected and X will be observed. If
the allele is uncommon, and if m is small compared to n, the
probability of X coming to our attention is approximately
proportional to X, and we have a size-biased sample. The size-
biased observation, X  is distributed as 1zB(n{1,p) [12], hence
X {1 is distributed as B(n{1,p). Removing the first detected
case from both numerator and denominator in the observed
fraction of cases yields an unbiased estimator of p, which may be
compared to the fraction of controls exhibiting the same allele,
even though controls are not subjected to allele discovery.
The size-biased situation is a limiting case, applicable to rare
alleles when the screened fraction is small. As we consider more
common alleles, the bias due to selective screening becomes less
that size-bias, and the practice of leaving out the first detection
becomes conservative. If the allele is so common that we would
very likely detect it in any sample of cases or controls, the fact that
we have not screened controls loses its relevance.
If the number screened for variants, m, is a substantial fraction
of the total number of cases, n, then the probability of observing
the allele approaches the probability that Xw0, rather than being
proportional to X. The simple omission of the first detected allele
can be too conservative in this situation. If one has the ability to
screen all cases for novel alleles, it is probably best to apply a
similar allele detection effort to controls as well.
Example: ATM exon 24. As a very simple example of
sequencing in selected cases we reconsider previously published
data on an uncommon variant in the ATM gene [13]. The cases
consist of 66 pairs of sisters with breast cancer. Controls are 126
cancer-free individuals with similar collective grandparental
ethnicity to that of the cases. Allele detection was concentrated
in a subset of 7 sib-pairs that shared a rare allele at the HRAS
minisatellite locus and also shared 1 or 2 intronic microsatellite
markers (NS22) at the ATM locus. The rationale was that rare
alleles at HRAS, which are associated with a two-fold increase in
the risk of breast cancer [14] as well as with an increased
propensity for double-strand breaks, may interact with high-risk
alleles at ATM, which participates in DNA double-strand break
repair [15]. Exon 24 sequence was obtained for the probands
of the 7 selected pairs, and two exhibited the same missense
variant altering an evolutionarily-conserved ATM residue
(C3161?G,Pro1054?Arg).
Having seen the same variant twice in a small number of
selected cases, sequence-specific genotyping was used on probands
from the remaining sib pairs, as well as controls. In particular, the
C-to-G polymorphism resulted in the loss of an Alw I restriction
site, so Alw I digestion and gel electrophoresis were used to screen
the remaining samples, identifying the variant in 7 additional cases
and 4 controls, as shown in Table 1. The original report omitted
all of the sequencing data from the primary calculation of
statistical significance. The results above, however, show that we
only need to omit the first observation of the G-to-C variant. The
Genotyping and Sequencing
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as significant in the context of hypothesis-driven research.
The exon 24 example only involves one variant, which is
uncommon, but still frequent enough to show up repeatedly.
Leaving out the first detection is obviously not an option for
private mutations that may only appear once. To help understand
the kinds of situations where this bias correction may be helpful,
we simulated its performance in comparison to a balanced
sequencing effort. Table 2 gives the simulation results for tests of
the collective association of rare alleles with disease. The naive
strategy means concentrating allele detection in cases only, while
counting all of the alleles from the discovery set together with non-
discovery genotyping. The corrected strategy refers to the omission
of initial detections in the discovery set, while including repeat
encounters. The balanced strategy refers to dividing the same
sequencing effort equally between cases and controls. The
complete strategy refers to applying allele detection, e.g. sequenc-
ing, to all cases and controls — which is an order of magnitude
more expensive. The various scenarios represent different
numbers of rare alleles, with various collective frequencies. A
dominant inheritance model is assumed, and we neglect the
probability of an individual exhibiting two rare variants.
The first four lines of Table 2 represent null hypothesis
scenarios, with a risk ratio of 1. The naive test has a seriously
inflated type I error rate, so it is not evaluated further. The other
tests are close to or below the nominal rate of 0.05. These exact
tests will be somewhat conservative due to discreteness.
In the scenarios with risk ratio of 2.5, assigning the sequencing
effort to cases, or balancing it between cases and controls both lead
to approximately the same power. Much higher power can of
course be had by sequencing all cases and all controls, but at much
greater expense. In the scenarios with higher allelic heterogeneity
but fewer individuals exhibiting any rare alleles, a greater
sequencing effort is necessary to maintain reasonable power.
The last line considers a smaller sample of 100 cases and 100
controls, so sequencing 100 cases exhausts the supply of cases. The
corrected test loses its power in this situation. The strategy of
sequencing only cases depends upon the availability of additional
genotyped cases exhibiting the same alleles that are detected by
sequencing. The balanced sequencing strategy maintains power in
the last scenario listed. Complete sequencing has higher power,
but involves twice as much sequencing effort.
More selective sequencing
We have shown that it is feasible to focus sequencing efforts on
cases, at least at the outset. We now consider how selective
sequencing enhances the detection of disease-related variants, and
how incorporation of family history and marker sharing can
further enrich the detection sample.
For a given number of cases and controls, an association test
based on genotyping will have better power if the cases have
affected siblings [16–18]. The requirement of family history
Table 1. ATM exon 24 allele counts from 66 independent
breast cancer cases and 126 unrelated controls.
Exon 24
Alleles Individuals
Disease
Status
Genotyping
Method C G variant/n Percent
Case Sequencing 12 2 2/7 (1/6) 29 (17)
Case Alw I digestion 111 7 7/59 12
Control Alw I digestion 248 4 4/126 3
The table summarizes data from Larson et al. [13]. The seven cases with
sequencing shared an intronic marker at ATM as well as a rare HRAS allele with
their affected sibling. Omitting the first occurrence of the variant among
sequenced cases (in parentheses) permits comparing a pooled detection rate of
8/65 in cases to 4/126 in controls (p~0:018 by Fisher’s exact test, one-sided).
doi:10.1371/journal.pone.0014318.t001
Table 2. Test size and power using detection in subsets.
Scenario Power (nominal pv0:05) Detected (mid 50%)
RR Rare Freq Seq Naive Corrected Balanced Complete Cases only Balanced
1 20 .2 50 .08 .05 .04 .04 (7, 9) (7, 9)
1 40 .2 50 .15 .04 .03 .04 (7, 10) (7, 10)
1 40 .1 50 .12 .03 .03 .04 (3, 6) (3, 6)
1 40 .05 100 .15 .01 .02 .03 (3, 6) (3, 6)
2.5 40 .2 50 NA .92 .89 1.00 (14, 17) (11, 14)
2.5 40 .1 50 NA .60 .58 1.00 (8, 11) (6, 9)
2.5 40 .1 100 NA .80 .85 1.00 (15, 19) (11, 15)
5 100 .05 100 NA .83 .89 1.00 (16, 21) (10, 14)
5 100 .05 100
1 NA .07 .63 .92 (16, 21) (10, 14)
1Number cases and controls reduced to 100, so sequencing exhausts cases.
For each line, except the last, 500 cases and 500 controls are generated in 5,000 simulated samples to estimate test size or power for a nominal 0.05-level test
comparing the collective frequency of rare alleles. In each scenario, the baseline disease rate is 1%, so relative risk (RR) of 2.5 implies a penetrance of 2.5%. Rare is the
number of unknown rare alleles in the population, all assumed to have the same frequency and penetrance. Freq is the total frequency of all rare alleles (e.g. 20 rare
alleles with a combined frequency of 0.2 imply a frequency of 0.01 each). We make the simplifying assumption that rare alleles are mutually exclusive. Seq is the total
number sequenced, either concentrated in cases or equally divided (balanced) among cases and controls. All four p-value columns are from Fisher’s exact text. The first
three count the number of cases and controls with any of the rare alleles detected among the indiduals that are sequenced. In the Naive and Corrected columns, all
sequences are from controls, but the number of detected distinct rare alleles is subtracted from the case count in the ‘Corrected’ column. Balanced indicates that the
individuals sequenced for allele detection were equally divided between cases and controls. Complete denotes the test based on sequencing all cases and all controls
— a much larger sequencing effort. The parenthetic numbers indicate 25th and 75th percentiles of the number of rare alleles detected in the cases-only and balanced
detection strategies.
doi:10.1371/journal.pone.0014318.t002
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opposed to purely sporadic cases. There is a second benefit, in that
the enrichment makes it easier to discover rare disease-related
alleles in the first place, so that genotyping efforts that depend on
pre-identified variants will capture more of the distinction between
cases and controls. Capitalizing on this aspect of family history
does not require that the entire sample of cases have affected
relatives. Only a subset with a family history need be identified to
permit limited sequencing resources to be focused on the cases
most likely to exhibit disease-related variants. In view of the
difficulty of discovering uncommon alleles, and the large effect of
allele misclassification on power [7], this second benefit may often
be important. So we consider, in this section, the effect of various
kinds of case selection directly on the probability of detecting
uncommon or rare alleles.
Selecting Cases. If we resequence affected individuals, the
probability of finding a rare allele is enhanced by a factor
approximately proportional to its relative risk. More precisely, if A
denotes the event that an individual has one or more copies of a
specific rare allele, with Ac denoting the complementary event,
and if D denotes the event that the individual has the disease, then
the probability of observing the rare allele in a given affected
individual is
P(AjD)~c P(A) ð1Þ
where
c ~
P DjA ðÞ
P D ðÞ
is a measure of relative risk. Another definition of relative risk is
c~P(DjA)=P(DjAc), but c  approximates c for uncommon
alleles with modest attributable risk.
Familial Cases. Requiring the resequenced cases to have a
family history will further enrich the discovery set for high-risk
variants. To be definite, consider families with two siblings, with
equal unconditional risk, denoted by P(D1)~P(D2), and let A1
refer to the presence of a specific high-risk allele in sibling number
one, whom we will arbitrarily call the proband. Then
P A1jD1D2 ðÞ ~
P D2jD1A1 ðÞ
P D2jD1 ðÞ
  
c P A1 ðÞ : ð2Þ
This states that the enrichment for high-risk alleles depends on the
increase in risk to a sibling due to the presence of a high-risk allele in
the proband. Roughly put, the sibling has about a 50 percent
chance of sharing the uncommon risk allele, so the relative
enrichment might approach about half again as much as that due
to case status, with the two enrichment factors being multiplicative.
A little more formally, we show in the methods section that the
approximation P(D1jD2Ac
1)&P(D1jD2), which seems reasonable
if the risk attributable to a given variant is modest, together with
the assumption of conditional independence of A2 and D1 given
A1 (or Ac
1), leads to
P A1jD1D2 ðÞ &
1zg
2
  
c P A1 ðÞ ð 3Þ
where
g~
P D1jD2A1 ðÞ
P D1jD2 ðÞ
:
Here g is a measure of relative risk due to the allele in the presence
of an affected sibling. For an allele that confers risk rather than
protection, we have g§1. If the other sources of risk to a relative
are limited, g might approach c , but if alleles at other loci are
important, g may be closer to 1, and further selection might be
needed to enrich the sample for risk alleles at the locus of interest.
Marker-Guided Case Selection. Selecting familial cases
enriches the sample for cases with a genetic etiology relative to
sporadic cases, but if there is genetic heterogeneity, the enrichment
may be spread across several genes. Further enrichment for high-
risk variants at a specific locus is possible by focusing resequencing
on cases that share one or two copies of a marker tightly linked to
that locus. It is only necessary that the markers identify whether
the relevant genomic region is shared identical by descent (IBD).
The markers do not need to be in linkage disequilibrium with any
risk alleles.
Because multiple selection criteria bring many details into play,
we explore their effect via numerical calculations based on explicit
scenarios. This is an extension of a previously described method
[7] (see methods). As above, we assume each proband has exactly
1 sibling at risk, with the joint probability of disease denoted
P(D1D2). A scenario consists of a model for the probability of
disease as a function of genotype, along with allele frequencies for
each gene in the model. We include a background rate of disease
which may represent sporadic cases, or the effect of genetic
background. We initially focus on a single locus, then briefly
investigate the impact of a second locus.
Table 3 gives the probability that an uncommon risk allele is
present in various strata, representing different levels of selection.
We consider two alleles and suppose there is a one percent disease
rate in individuals homozygous for the major allele, and a higher
rate in individuals with one or two copies of the minor allele, the
ratio given by c. We consider a minor allele frequency of 0.005, so
the minor allele is present in about one percent of the population
under study. The ratios of probabilities with different levels of
selection depend strongly on the relative risk, c. These are,
however, quite insensitive to both the absolute minor allele
frequency and the baseline probability of disease (data not shown).
The baseline probability of 0.01 was chosen to permit easy
interpretation.
From Table 3 we see that an allele present in one percent of a
population will, if it confers a doubled risk, be present in about two
percent of cases, about three percent of cases with affected siblings,
and about four percent of affected sibling pairs sharing two alleles
IBD at the locus. The median number of resequenced samples
needed to detect the minor allele would drop from 69 in
unselected cases, to 38 in cases, to 18 with marker sharing. The
factor by which increasingly selective resequencing enhances the
detection of disease-associated variants increases dramatically with
the relative risk. If rare alleles do tend to have high penetrance,
then selective resequencing seems likely to pay off well.
We examined the robustness of these results by modeling the
effect of a second locus with a somewhat more common high-risk
allele, also with a dominant effect, that adds 1 percent risk (a two-
fold increase over baseline). The second locus can also represent
two classes of genotype, as might occur if there are several
dominant alleles with similar penetrance. The results are shown in
the lower half of Table 3. The ability of case selection to enhance
Genotyping and Sequencing
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somewhat attenuated under this additive model.
If the variant (or class) at the nuisance locus is known, then
selection for the absence of this alternative etiology would
substantially restore the enrichment. A similar idea seems to have
guided an investigation of the CHEK2 gene in breast cancer that
was carried out using non-carriers of BRCA1 or BRCA2 mutations
[19]. Further calculations (not shown) indicate that exclusion of
cases with a likely alternative etiology can enhance the detection of
rare alleles under an additive model. Under an interaction model,
however, detection of the rare variant can be enhanced by
including, rather than excluding, the cases with the high-risk
variant at the second locus. This behavior is consistent with the
previous discussion of the limits of the parameter g in equation (3).
The correct use of information from a second locus of established
relevance depends on its relationship to the locus under investiga-
tion. If genetic heterogeneity is more likely than strong positive
interaction, then omission of cases with an explainable etiology
would be the preferable strategy. In the ATM exon 24 example,
described above, we selected cases sharing a rare HRAS allele and
one or two ATM alleles with an affected sibling, on the hypothesis
that the functions of HRAS and ATM would imply an interaction.
Focusing on Rare Variants
Cases-only sequencing and selective sequencing are useful for
uncommon variants. The study of rare variants requires resequen-
cing of all cases and controls. We may then wish to focus exclusively
on rare variants, motivated by the hypothesis that rare variants are
the primary source of risk. Focusing exclusively on rare variants
would then avoid diluting the effect size of a collective test, and may
elucidate a class of variants of some predictive value.
One can focus on rare variants by omitting alleles that are
known from a sequence database, but neutral alleles of modest
frequency may not have been catalogued. We consider two
approaches for limiting attention to rare alleles. One approach is
to limit attention to group-specific variants, i.e. sequences that only
appear in cases or only appear in controls, but not in both [20].
This would include both rare mutations and uncommon mutations
of high penetrance. The other approach is to use genotyping in
pooled samples to screen for the putative rare sequences in a very
large number of individuals [21]. This approach can economically
focus attention on what are essentially private mutations, without
regard to penetrance.
Group-specific sequences. An advantage of comparing the
frequency of group-specific variants is that a variant may be
restricted to cases because it is rare, or because its penetrance is
sufficiently high that it does not appear among the controls. The
main disadvantage is that the validity of the comparison depends
on equal numbers of cases and controls, as described below. If
there are variants that confer protection as well as risk, both will
tend to be included, but this is a fundamental problem of testing a
collection of rare variants.
To demonstrate the requirement for equal sample sizes,
consider a population containing a set of rare variants indexed
by i~1,...M. Let X1i be the number of detections of variant i
among n1 cases, and let X2i be the number of detections among n2
controls. The group-specific inclusion scheme amounts to
simultaneously replacing X1i by 0 if X2iw0, and replacing X2i
by 0 if X1iw0. We can compare cases to controls by computing
D~
X M
i~1
X1i=n1{
X M
i~1
X2i=n2
and comparing D to its standard error. Under the null hypothesis,
for a given i, X1i and X2i have independent binomial distributions,
with common rate pi and indices n1 and n2. Denote these binomial
probability functions by f1i(x) and f2i(x). Then the weighted joint
probability function, after applying the selection criterion, is
f  
i (x,y)!w(x,y)f1i(x)f2i(y) where w(x,y)~0 if both xw0 and
yw0, and w(x,y)~1 otherwise. Substituting the binomial
probability for f2i(0) and summing over y, we obtain the marginal
probability function for cases,
f  
1i(x)~(1{pi)
n2f1i(x)i f xw0
Table 3. Detection Probabilities for High-Risk Variants.
Selection ª~1:5 ª~2:0 ª~3:0 ª~5:0
Single gene model
All Individuals 0.010 0.010 0.010 0.010
Cases 0.015 0.020 0.029 0.048
w/affected sibs 0.019 0.029 0.057 0.130
sharing 1 or 2 IBD 0.020 0.032 0.066 0.155
sharing 2 IBD 0.022 0.039 0.083 0.201
With a second, nuisance locus
All Individuals 0.010 0.010 0.010 0.010
Cases 0.014 0.019 0.028 0.045
w/affected sibs 0.017 0.026 0.049 0.109
sharing 1 or 2 IBD 0.018 0.029 0.056 0.130
sharing 2 IBD 0.020 0.034 0.070 0.169
In each scenario there is a sporadic disease rate of 1% and the high-risk allele of interest elevates the disease risk by a factor of c, which varies across columns. The rows
represent increasingly restrictive sampling rules, and the probability that the high risk allele is present (one or two copies) in a sampled proband is tabulated. In the
upper half of the table, risk depends only on one locus. In the lower half, there is also a nuisance locus, with a 5 percent allele frequency, i.e. 10 times as common as the
allele of interest, and additive with its effect.
doi:10.1371/journal.pone.0014318.t003
Genotyping and Sequencing
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1i(0), determined by subtraction from
1, and a similar expression for f  
2i(y) applying to controls. It is
apparent at this point that the condition n1~n2 is sufficient to
ensure that E(D)~0 under the null hypothesis, i.e. our estimate of
the difference in rare variant frequency is unbiased.
If n1=n2, however, there can be a substantial bias. As a
demonstration, we generated allele frequencies for a hypothetical
locus with 100 variants ranging in frequency from approximately
0.6 to 0.00006. Because of the uncertainty about the likely
distribution of rare alleles and our limited purpose, we arbitrarily
took variant frequencies to be k=i2 where i~5,10,15,...,500, and
the normalization constant, k is 15.2. This resulted in approxi-
mately 83% of the total allele frequency in 3 common alleles, 12%
in 8 uncommon alleles, and 5% in 89 rare alleles, including 1.9%
in the 76 with detection probability less than 0.001. If 1000 case
and 1000 control sequences are sampled under the null hypothesis,
many of these 100 alleles would not be detected, and the expected
count of group-specific detections is 16 in cases and 16 controls,
based on a Poisson approximation. If there is a marked difference
in sample size, say 1200 case and 800 control sequences, we
expect 22 group-specific detections among cases, but only 11
among controls, the expected rates being .0185 versus .0141, for
a bias of approximately 27 percent (%L [22], calculated as
100loge (0:0185=0:0141)). The bias arises because the larger
group will exert a disproportionate suppression of the counts in the
smaller group. With a more modest imbalance of 950 cases and
1050 controls, the bias is about 7%L.
Adding another 100 very rare alleles (with little change in the
total frequency of common, uncommon and rare alleles) increased
the expected number of group-specific dections from 16 to 19 per
group,buthadlittleeffectonthebias (23%Lwith1200 v.800; 6%L
with1050 v. 950). The bias is mainly determined by the uncommon
alleles that may or may not be encountered more than once.
The amount of bias depends on the specific set of allele
frequencies, as well as the degree of imbalance, but this arbitrary
example shows that the bias can be appreciable. The comparison
of group-specific variants, while appealing in concept, seems to
require rather close matching of sample sizes.
An excess of group-specific variants at the ATM gene has been
reported in breast cancer [20]. Comprehensive ATM mutation
screening of all coding exons and splice junctions has been carried
out using the DOVAM-S [23,24] method, which is comparable to
sequencing for mutation detection. Variants affecting protein
structure or expression were found in 23 of 90 women with breast
cancer, and 13 of 90 women without breast cancer (p~:046, one-
sided Fisher’s exact test). The association of group-specific variants
with breast cancer was stronger, finding 14 in 90 cases, but only 4
in 90 control samples (p~:012). We speculate that the stronger
group-specific result reflects higher average penetrance due to
better exclusion of neutral variants from the collection. We also
note that collective testing is predicated on a common direction of
effect, which implies that one-sided tests are appropriate.
Pooled-sample screening. A more laborious but more
direct way to restrict attention to rare alleles is to limit the
events counted among cases and controls based on a third sample.
Highly sensitive detection methods [25] now make it possible to
follow the sequencing of cases and controls by probing for
additional instances of the newly detected variants in a very large
number of individuals through the use of a feasible number of
pooled samples. This approach has been used to demonstrate that
rare missense variants found in schizophrenia patients were not
present in 10,000 control alleles [21].
We can represent this strategy by writing the joint distribution
of detections for sequence i as f  
i (x,y)!wif1i(x)f2i(y), where the
ascertainment weight function, wi is 0 if the sequence i is detected
in the third sample, and 1 if it is not. This is not dependent on
either x or y. Under the null hypothesis, f1i and f2i are binomial
distributions with a common rate parameter, pi,s o
E(X1i=n1)~E(X2i=n2) for all i, hence E(D)~0 under the null
hypothesis.
The selection of sequences absent from a supplementary sample
eliminates some of the terms in both sums contributing to D, but it
does not distort the distribution of any of the remaining terms, and
so leaves the estimated difference unbiased for the the correct
value of zero under the null hypothesis. The value of the selection
depends on the alternative hypothesis, i.e. on the correctness of the
belief that rare alleles will tend to have a larger average
penetrance, and therefore a larger relative difference in detection
rates. The power benefits of selecting rare alleles may depend on
the details of this assumption. The point here, however, is that
selection of sequences based on a third sample does not raise any
validity issues.
Discussion
In this paper, we provide three results of wide applicability
rather than a prescriptive method. We focus primarily on a simple
case-control setting, and a simple test of the collective effect of
uncommon or rare alleles.
At present, resequencing on a substantial scale needs to be
targeted to a specificlocus [26]. Attemptingto expand the catalogue
of genetic variation at a locus might be encouraged by a belief that
rare alleles will have larger effects than common alleles. The finding
herelendsfurtherencouragement,inthathigherpenetranceislikely
to translate into easier detection among cases, with the effect of
penetrance being magnified as resequencing becomes more
selective. Focusing sequencing efforts on the subset of cases that
report a positive family history can increase the yield of disease-
associated variants, a phenomenon closely related to the power
advantage that has been noted when cases have affected relatives.
The advantage of focusing limited sequencing resources can be
obtained, however, by the opportunistic enrollment of siblings, or
even by simply collecting family history data. It does not necessarily
require any efforts to enhance the recruitment of familial cases,
although the power advantages of such efforts still apply.
The identification of a subset of cases most likely to harbor
disease-associated variants at a locus may permit the use of a more
powerful test statistic that capitalizes on the hypothesized ordering
of controls, cases, and select cases, with regard to the prevalence of
rare variants. A test for a trend in proportions can be applied to
the data in Table 1, for example, but due to the adjustment for
cases-only sequencing, the result is not much different from that
comparing all cases to controls. If the same results had come from
sequencing, however, without need for adjustment, the p-value
would be reduced to .004 (exact Cochran-Armitage test), reflecting
the enrichment for rare variants in the selected group. While the
use of marker-sharing for case selection is only applicable to locus-
specific sequencing, the sharing of markers among affected siblings
can be used as part of the statistical analysis in genome-wide
sequencing studies. Madsen and Browning [27], for example,
propose assigning scores to individuals, based on the number an
type of mutations present. Including marker-sharing information
in such scores would be a natural extension, although it would
complicate the null distribution, taking the idea beyond the scope
of this paper. The idea does, however, suggest how to extend the
use of marker sharing from the the locus-specific sequencing
setting considered here, to the setting of exome or genome
sequencing.
Genotyping and Sequencing
PLoS ONE | www.plosone.org 6 December 2010 | Volume 5 | Issue 12 | e14318The need to discard first encounters when combining cases-only
sequence data with case and control genotyping has different
implications in different situations. When many unique variants
are encountered, extensive resequencing of both cases and controls
is necessary. When most variants have sufficient frequency to be
repeatedly detected, the simple bias correction of omitting the first
encounter is competitive with a balanced resequencing effort.
This, together with the expense of resequencing, makes it natural
to start with cases, perhaps supplemented by family history and
marker data. If multiple uncommon alleles are encountered more
than once, an expansion of the study using genotyping might be
indicated. If mostly rare alleles are discovered, without repeated
detection, a larger resequencing effort that includes controls might
be planned.
Whether the comparison of cases to controls should be
restricted to rare variants, common alleles, or both, may depend
on previous work, and the attitude of the investigator about the
likely effects of rare or common variants. There does not seem to
be much difficulty with the use of external data to select the alleles
of interest, provided that the supplemental data are not used as
frequency data in the comparison. Selecting rare sequence variants
based on group-specific detection provides advantages of economy
and adaptively relaxing the rarity requirement as penetrance
increases. It is important to note, however, that this approach
requires equal sample sizes for validity.
Methods
To derive equation 3, we assume that the variant of interest is
sufficiently uncommon that we may neglect bi-lineal inheritance.
Then we can write
P(D2jD1A1)~P(D2Ac
2jD1A1)zP(D2A2jD1A1)
~P(D2jD1A1Ac
2)P(Ac
2jD1A1)
zP(D2jD1A1A2)P(A2jD1A1)
~P(D2jD1A1Ac
2)P(Ac
2jA1)zP(D2jD1A1A2)P(A2jA1)
~
1
2
P(D2jD1A1Ac
2)z
1
2
P(D2jD1A1A2):
The first equality follows from the law of total probability, the
second from the definition of conditional probability, the third
from assuming conditional independence of A2 and D1 given A1,
and the last from neglecting bilineal inheritance of the rare allele.
The symmetry of the sibling labels means that we are also
assuming that D2 is independent of A1 given A2 (or its
compliment), so
P(D2jD1A1)~
1
2
P(D2jD1Ac
2)z
1
2
P(D2jD1A2)
~
1
2
P(D1jD2Ac
1)z
1
2
P(D1jD2A1)
&
1
2
P(D1jD2)z
1
2
P(D1jD2A1):
The second equality follows again from the symmetry of the siblings,
and the approximate equality follows from our initial assumption that
P(D1jD2Ac
1)&P(D1jD2). Substituting for P(D2jD1A1) in equation
2, and observing that P(D2jD1)~P(D1jD2), yields equation 3.
In order to consider the effects of marker-based selection of
cases, we explicitly compute the joint distribution of genotypes in a
pair of siblings, and their joint disease status, conditional on the
number of genes shared identical by descent (IBD) at a specified
locus. This is an extension of a previously published renormaliza-
tion method for calculating case and control allele frequencies
from prospectively specified models [7]. Briefly, Let yp~1 if the
proband is affected, and zero otherwise. Let ys be similarly defined
for the sibling. Let xp and xs represent the proband and sibling
genotypes, Let i be the number of alleles shared identical by
descent at a given gene, with probabilities p(i). The conditional
distribution of proband genotypes is given by
p(xpjyp,ys,i)!
X
xs
p(ypjxp)p(ysjxs)p(xp,xs,i)
where the penetrance model specifies p(ypjxp), which is the same
function as p(ysjxs), and where p(xp,xs,i)~p(xp,xsji)p(i) is easily
calculated assuming Mendelian segregation and Hardy-Weinberg
genotype proportions. (We are here abusing notation to let
arguments distinguish probability functions.) By working with ibd
status directly, we approximate the effect of selection based on
highly informative markers.
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